Michael Burgess actually said...

It is important. I am glad we are able to come together in a bipartisan fashion to make this happen.

Reauthorizing improved generic and biosimilar user fee programs will lead to timelier approvals and lower drug costs. It's that simple.

We must remain vigilant in ensuring government does not get in the way of the very innovation that can keep us safe.

When I was Chairman of the Commerce, Manufacturing, and Trade Subcommittee we dedicated a lot of time to self-driving cars and their ability...